Zoetis Expands Feline Pain Management Portfolio with Portela Launch in Canada and EU
Event summary
- Zoetis launched Portela® (relfovetmab), a long-acting anti-NGF monoclonal antibody therapy for feline osteoarthritis pain, in Canada and the EU on July 22, 2026.
- Portela offers up to three months of pain relief per subcutaneous injection, addressing compliance challenges with oral medications.
- The product is backed by a nine-month European field study showing efficacy from as early as Day 3 post-injection.
- Zoetis aims to close the gap in feline osteoarthritis diagnosis and treatment, a condition affecting up to 40% of cats but often overlooked.
The big picture
Zoetis’ launch of Portela underscores the growing focus on chronic pain management in companion animals, particularly as cats live longer due to advancements in veterinary care. The product addresses a critical unmet need for convenient, effective treatments in an underserved segment of the animal health market. With Portela joining Solensia in its feline osteoarthritis portfolio, Zoetis strengthens its position in a niche where compliance and long-term management are key differentiators.
What we're watching
- Market Adoption
- How quickly veterinarians and pet owners will embrace Portela’s long-acting formulation, given the historical underdiagnosis of feline osteoarthritis.
- Competitive Dynamics
- Whether Zoetis can sustain its leadership in feline pain management with Portela complementing Solensia’s monthly treatment option.
- Regulatory Scrutiny
- The pace at which other regions may approve Portela, given its novel mechanism of action and long-acting profile.